Nordic Nanovector

Vær den første som følger denne virksomhed

ViserAlle indholdstyper

Selskabsmeddelelse20.12.2024, 14.06

Thor Medical ASA: Notification of trade for close associate of primary insider

Nordic Nanovector

Selskabsmeddelelse20.12.2024, 13.26

Thor Medical ASA: Disclosure of large shareholding

Nordic Nanovector

Selskabsmeddelelse20.12.2024, 13.23

Thor Medical ASA: Disclosure of large shareholdings and notification of transaction by close associates of primary insiders

Nordic Nanovector

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account

Followings and notifications on followed companies

Analyst comments and recommendations

Stock comparison tool & other popular tools

Selskabsmeddelelse20.12.2024, 13.17

Thor Medical ASA - Share capital increase in relation to Tranche 1 of the Private Placement and the PrimaryBid Offering is registered

Nordic Nanovector

Selskabsmeddelelse19.12.2024, 06.45

TRMED: Thor Medical and AdvanCell sign strategic supply agreement for Thorium-228

Nordic Nanovector

Selskabsmeddelelse16.12.2024, 19.34

Thor Medical ASA - Notice of Extraordinary General Meeting on 6 January 2025

Nordic Nanovector

Selskabsmeddelelse12.12.2024, 06.00

Thor Medical ASA: Ex. right to participate in subsequent offering today

Nordic Nanovector

Selskabsmeddelelse11.12.2024, 23.59

Thor Medical ASA: Disclosure of large shareholding - share lending

Nordic Nanovector

Selskabsmeddelelse11.12.2024, 23.55

Thor Medical ASA: Allocation of shares to primary insiders and their close associates in the Private Placement

Nordic Nanovector

Selskabsmeddelelse11.12.2024, 23.43

Thor Medical ASA: Key information relating to potential subsequent offering

Nordic Nanovector

Selskabsmeddelelse11.12.2024, 23.31

Thor Medical ASA: Private placement successfully completed

Nordic Nanovector

Selskabsmeddelelse11.12.2024, 15.30

Thor Medical ASA: Contemplated private placement and retail offer via PrimaryBid

Nordic Nanovector

Selskabsmeddelelse25.11.2024, 06.00

Thor Medical capital markets update: Enabling next-generation precision cancer treatments

Nordic Nanovector

Selskabsmeddelelse22.11.2024, 06.45

TRMED: Thor Medical signs agreement for supply of Pb-212 for pre-clinical use with globally leading pharmaceutical company

Nordic Nanovector

Selskabsmeddelelse19.11.2024, 06.30

TRMED: Thor Medical ships first product sample to potential customer from Herøya pilot facilities

Nordic Nanovector

Selskabsmeddelelse1.11.2024, 06.00

TRMED: Thor Medical invitation to capital markets update

Nordic Nanovector

Selskabsmeddelelse30.9.2024, 19.34

TRMED: Disclosure of large shareholding

Nordic Nanovector

Selskabsmeddelelse26.9.2024, 06.00

TRMED: Thor Medical completes Herøya pilot facilities and initiates commissioning

Nordic Nanovector

Selskabsmeddelelse30.8.2024, 05.00

Thor Medical ASA reports first half 2024 results - Pilot facility progressing as planned and targeting 'fast-track' scale-up to commercial production

Nordic Nanovector

Selskabsmeddelelse16.8.2024, 05.00

TRMED: Invitation to presentation of Thor Medical ASA's first half results 2024

Nordic Nanovector

Inderes’ ansvarsfraskrivelse kan findes her. Detaljeret information om hver aktie, der aktivt overvåges af Inderes og HC Andersen Capital, er tilgængelig på de virksomhedsspecifikke sider på Inderes' hjemmeside. © Inderes Oyj. All rights reserved.